🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Kim Boesen

Copenhagen University Hospital

ORCID: 0000-0001-8963-8585
Decision SciencesMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile
0.280Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

FDA and EMA clinical research guidelines: Assessment of trial design recommendations for pivotal psychiatric drug trials (Protocol)

medRxiv(2020)10.1101/2020.01.22.20018499
Top 57%
0.280DataRank
Top 57%3 citations

Peter C. Gøtzsche, John P. A. Ioannidis, Kim Boesen

Papers

Driven by 6 papers — median percentile 22. Top paper: “Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults”.

Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults

Cochrane Database of Systematic Reviews(2017)10.1002/14651858.cd012857
N/A
0.608DataRank · unranked
12 citations

Pia Brandt Danborg, Peter C Gøtzsche, Karsten Juhl Jørgensen, Kim Boesen

Results reporting for clinical trials led by medical universities and university hospitals in the nordic countries was often missing or delayed

Journal of Clinical Epidemiology(2025)10.1016/j.jclinepi.2025.111710
N/A
0.360DataRank · unranked
10 citations

Susanne Wieschowski, Maia Salholz-Hillel, Love Ahnström, Tarik Suljic, Samruddhi Yerunkar +37 more

FDA and EMA clinical research guidelines: Assessment of trial design recommendations for pivotal psychiatric drug trials (Protocol)

medRxiv(2020)10.1101/2020.01.22.20018499
Top 57%
0.280DataRank
Top 57%3 citations

Peter C. Gøtzsche, John P. A. Ioannidis, Kim Boesen

Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed

medRxiv(2024)10.1101/2024.02.04.24301363
N/A
0.165DataRank · unranked
2 citations

Susanne Wieschowski, Nicholas J. DeVito, Maia Salholz-Hillel, Love Ahnström, Till Brückner +37 more

Requesting conflicts of interest declarations from the European Medicines Agency: 3-year follow-up status

Epidemiology and Psychiatric Sciences(2024)10.1017/s2045796024000179
N/A
0.104DataRank · unranked
1 citations

John P. A. Ioannidis, Peter C. Gøtzsche, Kim Boesen

Considering the methodological limitations and external validity issues of pharmacological drug trials in adult ADHD: An umbrella review (Open Protocol)

medRxiv(2021)10.1101/2021.12.07.21267067
Top 100%
0DataRank
Top 100%0 citations

Asger Sand Paludan-Müller, John P. A. Ioannidis, Asger Sand Paludan‐Müller, Kim Boesen